ATP6V0D2
V-type proton ATPase subunit d 2
Also known as: ATP6D2, FLJ38708, VA0D2_HUMAN, VMA6
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q8N8Y2
- Gene
- ATP6V0D2
- Ensembl
- ENSG00000147614
- Chromosome
- 8
- Canonical length
- 350 aa
- Protein class
- Metabolic proteins, Predicted intracellular proteins
- Subcellular location
- Vesicles
OverviewNCBI Gene
Predicted to enable proton-transporting ATPase activity, rotational mechanism. Predicted to be involved in vacuolar acidification and vacuolar transport. Located in apical plasma membrane. Part of vacuolar proton-transporting V-type ATPase complex. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
350 residues, UniProt reviewed canonical sequence.
>Q8N8Y2|ATP6V0D2
1 MLEGAELYFN VDHGYLEGLV RGCKASLLTQ QDYINLVQCE TLEDLKIHLQ TTDYGNFLAN
61 HTNPLTVSKI DTEMRKRLCG EFEYFRNHSL EPLSTFLTYM TCSYMIDNVI LLMNGALQKK
121 SVKEILGKCH PLGRFTEMEA VNIAETPSDL FNAILIETPL APFFQDCMSE NALDELNIEL
181 LRNKLYKSYL EAFYKFCKNH GDVTAEVMCP ILEFEADRRA FIITLNSFGT ELSKEDRETL
241 YPTFGKLYPE GLRLLAQAED FDQMKNVADH YGVYKPLFEA VGGSGGKTLE DVFYEREVQM
301 NVLAFNRQFH YGVFYAYVKL KEQEIRNIVW IAECISQRHR TKINSYIPILLocalizationUniProt · AlphaFold · HPA
Whether an antibody against ATP6V0D2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.26
- Highest tissue expression
- 56 nTPM
Expression across tissuesHPA
Tissue
- kidney: 56 nTPM
- retina: 13 nTPM
- rectum: 3.3 nTPM
- colon: 2.9 nTPM
- lung: 2.4 nTPM
- seminal vesicle: 2.3 nTPM
Single-cell type
- renal collecting duct intercalated cells: 1,373 nCPM
- epididymal clear cells: 792 nCPM
- cone photoreceptor cells: 329 nCPM
- rod photoreceptor cells: 299 nCPM
- salivary ionocytes: 191 nCPM
- distal convoluted tubule cells: 184 nCPM
Immune cell
- neutrophil: 1 nTPM
- basophil: 0.6 nTPM
- NK-cell: 0.4 nTPM
- plasmacytoid DC: 0.4 nTPM
- naive B-cell: 0.3 nTPM
- gdT-cell: 0.2 nTPM
Brain region
- basal ganglia: 6.6 nTPM
- midbrain: 6.3 nTPM
- white matter: 6.1 nTPM
- thalamus: 6 nTPM
- cerebral cortex: 5.9 nTPM
- hypothalamus: 5.1 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.4
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.77
- DepMap mean gene effect
- -0.06
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
- rotational mechanism
- proton-transporting ATPase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of ATP6V0D2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads ATP6V0D2 as an antibody target. Whether an autoantibody or antibody against ATP6V0D2 could matter depends on whether native ATP6V0D2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
ATP6V0D2 is annotated at the cell surface, where native ATP6V0D2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label ATP6V0D2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...